Latest news with #AGBT
Yahoo
03-03-2025
- Business
- Yahoo
Quantum-Si (NasdaqGM:QSI) Leaps 23% With New Platinum Pro Sequencer Unveiling
Quantum-Si recently announced its participation in the upcoming AGBT meeting, highlighting its advancements in Next-Generation Protein Sequencing, alongside establishing a Scientific Advisory Board aimed at guiding scientific strategy. These announcements come at a time when the company reported a significant share price move of 23%, suggesting strong investor interest. During the last quarter, the company's stock performance was bolstered by the introduction of new products such as the Platinum Pro sequencer and the Platinum Library Prep Kit, V2, both of which are designed to enhance protein analysis efficiency. Concurrently, the market has experienced mixed trends with major indices showing slight losses due to concerns about economic health, inflationary pressures, and tariffs. However, Quantum-Si's technological innovations and strategic developments in protein sequencing have likely positioned it to stand out amid broader market uncertainties, contributing favorably to its recent total shareholder returns. Click to explore a detailed breakdown of our findings on Quantum-Si. Over the past year, Quantum-Si's total shareholder return, including share price and dividends, was a decline of 25.41%. During the same period, the US Market experienced a return of 15.3%, highlighting Quantum-Si's underperformance. Several key developments influenced the company's performance. In November 2024, Quantum-Si received a Nasdaq delisting notice for falling below the minimum bid price, a significant regulatory challenge. The collaboration with NVIDIA, announced in November 2024, aimed to enhance their Proteus platform using AI for faster data processing. Additionally, the company expanded its international distribution network in December 2024, reflecting efforts to broaden its market reach. The introduction of the Platinum Pro sequencer in January 2025 was a crucial product-related development, featuring advanced capabilities for protein analysis. The formation of a Scientific Advisory Board in February 2025, including experts like Dr. Gloria M. Sheynkman, was aimed at guiding Quantum-Si's scientific strategies. Despite these initiatives, the company remains unprofitable, facing an increased net loss of US$25.31 million for Q3 2024, compared to the previous year. Learn how Quantum-Si's intrinsic value compares to its market price with our detailed valuation report. Assess the downside scenarios for Quantum-Si with our risk evaluation. Already own Quantum-Si? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGM:QSI. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Associated Press
24-02-2025
- Health
- Associated Press
Leisa Zigman Joins The Genome Partnership Board
The Genome Partnership, the organization that hosts the renowned Advances in Genome Biology and Technology (AGBT) meetings, announced today at its 25th anniversary AGBT General Meeting that former AGBT president Leisa Zigman has joined its board of directors. Zigman, a respected journalist and former AGBT president, brings a wealth of leadership experience and a deep commitment to advancing genomics research and collaboration. Her tenure as president saw significant growth in AGBT's impact, fostering scientific innovation and strengthening the organization's position as a premier convenor of the genomics community. 'Leisa's contributions to AGBT have been instrumental in shaping the success of our meetings and mission,' said Wendy Vlieks, president of The Genome Partnership. 'Announcing her appointment at our 25th anniversary General Meeting is especially fitting, as she has played a key role in AGBT's evolution. We are thrilled to have her join The Genome Partnership board, where her insights and expertise will continue to drive our commitment to advancing discovery and innovation in genomics.' Zigman's leadership has been pivotal in expanding AGBT's reach across key areas of genomic science, including precision health, agriculture and foundational research. As a board member, she will support strategic initiatives that enhance The Genome Partnership's role in fostering meaningful scientific exchange and collaboration. 'Leisa has been a driving force behind AGBT's growth and influence,' said Richard Wilson, chair of The Genome Partnership board and executive director of the Institute for Genomic Medicine at Nationwide Children's Hospital. 'Her leadership and vision have helped shape the genomics community, and I have no doubt that she will continue to be an invaluable asset to The Genome Partnership in this new role.' 'I am honored to join The Genome Partnership board and look forward to supporting its mission in this new capacity,' Zigman said. 'The organization has long been a catalyst for transformative genomics research, and I am excited to contribute to its continued success.' For more than 25 years, The Genome Partnership has provided a forum for researchers, industry leaders and policymakers to discuss the most groundbreaking advances in genomics. With Zigman's appointment, the organization reinforces its dedication to leadership and excellence in the field. About The Genome Partnership The Genome Partnership is a not-for-profit organization committed to advancing research, promoting education and fostering dialogue in genomics and life sciences. Through its globally recognized AGBT meetings, the organization convenes leading experts to discuss cutting-edge scientific advancements and applications. SOURCE: The Genome Partnership Copyright Business Wire 2025. PUB: 02/24/2025 08:10 AM/DISC: 02/24/2025 08:10 AM
Yahoo
19-02-2025
- Business
- Yahoo
Illumina To Webcast Upcoming Investor Session at the Advances in Genome Biology and Technology (AGBT) Conference
SAN DIEGO, Feb. 18, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that investors, analysts, and other interested parties can access a live webcast of its upcoming investor session at the AGBT conference. The investor fireside chat will begin at 8:00am Pacific Time (11:00am Eastern Time) on Tuesday, February 25, 2025 and will feature Jacob Thaysen (Chief Executive Officer), Ankur Dhingra (Chief Financial Officer), and Steve Barnard (Chief Technology Officer). Interested parties may access the live webcast via the Investor Info section of Illumina's website or directly through the following link – ( To ensure timely connection, please join at least ten minutes before the scheduled start of the session. A replay will be posted on Illumina's website after the event and will be available for at least 30 days following. About Illumina Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit and connect with us on X (Twitter), Facebook, LinkedIn, Instagram, TikTok, and YouTube. Investors: Salli Schwartz +1.858.291.6421 ir@ Media:Bonny Fowler+1.740.641.5579pr@ View original content: SOURCE Illumina, Inc.
